Boulder, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Lanterne Dx, LLC, a discovery and clinical phase CRO offering histopathology and biomarker validation services to pharmaceutical and biotech customers, today announced it has completed its merger with Flagship Biosciences, Inc., a computational biology, data science, and digital pathology company backed by Ampersand Capital Partners. The combined organization will operate under the Lanterne Dx name.
The merger combines Lanterne Dx’s CAP/CLIA-accredited histopathology and biomarker laboratory capabilities with Flagship Biosciences’ expertise in computational pathology, image analysis, and regulatory support. Together, the organizations provide an expanded, integrated platform supporting drug development from early discovery and translational research through clinical development.
For customers, the combination offers broader capabilities, increased scientific and technical depth, and a single partner across the histopathology, biomarker, and digital pathology workflow.
“This merger reflects our strategy of building a more comprehensive biomarker and digital pathology services platform for our customers,” said Jon Bishop, CEO of Lanterne Dx. “By bringing Flagship Biosciences’ AI-powered image & computational analysis expertise together with Lanterne Dx’s histopathology and biomarker capabilities, we are able to offer a broader, more integrated set of services to our clients. We are proud of what both teams have built and excited for what this combined organization can deliver.”
Jon Bishop, founder and CEO of Lanterne Dx, will lead the combined organization as Chief Executive Officer. Tom Turi PhD, CEO of Flagship Biosciences, will retire by the end of the year following the close of the transaction.
“Joining forces with Lanterne Dx is a logical next step for Flagship Biosciences and its customers,” said Tom Turi. “I have great confidence in Jon and the team to build on the platform we’ve created together. I’m deeply grateful for my time at Flagship, and I’m looking forward to beginning this next chapter.”
About Lanterne Dx
Founded in 2019, Lanterne Dx is a full-service histopathology CRO providing discovery, translational, and clinical biomarker services. The CAP/CLIA-accredited laboratory specializes in biomarker development, including antibody development, optimization, and validation, with capabilities spanning IHC, IF, multiplexing, ISH, FISH, pathology evaluation, image analysis, and data analysis.
About Flagship Biosciences, Inc.
Founded in 2009, Flagship Biosciences, Inc. is a computational pathology and digital tissue analysis company specializing in AI-powered image analysis, tissue analysis, and scientific interpretation to support drug development and diagnostics.
About Ampersand Capital Partners
Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with over $4 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, Amsterdam, and London, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit www.ampersandcapital.com or follow us on LinkedIn.
Attachments
